OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Inflammatory arthritis affects men’s fertility	621
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	407
Bimekizumab effective across the axSpA spectrum	351
No benefit from adding MTX to ustekinumab	337
Low-dose rituximab can go even lower	308
Genome-wide mutagenesis reported in systemic sclerosis	261
Rheumatic diseases on the rise	235
A role for TGFβ and EBV in MIS-C pathogenesis	215
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	205
Biological and clinical roles of IL-18 in inflammatory diseases	186
Targeting articular Mmp13 in OA	175
New drug formulation reduces bone loss	172
FOXP3 splice variant is associated with autoimmune disease	168
Towards better management of sterile bone inflammation	153
Use of platelet-rich plasma for knee OA not supported by RCT results	152
MIS-C: myths have been debunked, but mysteries remain	151
Inflammation across tissues: can shared cell biology help design smarter trials?	148
Which NSAIDs are best for OA treatment?	132
2021 ACR guideline for JIA reflects changes in practice	121
The 2022 ACR vaccination guideline: a call-to-action	121
Urchin-like nanoparticles for miRNA therapy of OA	121
The value of comparative efficacy studies in informing rheumatology guidelines	120
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	113
Down syndrome: insights into autoimmune mechanisms	109
To choose or not? The value of discrete-choice experiments in rheumatology	109

Ageing stem cells hold the key to age-related bone degeneration	104
Appraising the evolving landscape of protease inhibition in osteoarthritis	100
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	99
Co-trimoxazole reduces mortality in anti-MDA5-DM	97
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	97
Low-dose glucocorticoids benefit seniors with RA	95
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	93
Wnt-induced IGF1 drives OA	93
Calprotectin tracks tocilizumab-treated RA	93
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	89
Author Correction: Proposals for the rheumatological use of JAK inhibitors	88
Guiding ILD management in systemic autoimmune rheumatic diseases	87
A direct link between SARS-CoV-2 and bone loss	84
Rheumatic diseases and metabolism: where centre and periphery meet	83
Fumarate drives interferon release in systemic sclerosis monocytes	82
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	80
Low back pain is a growing concern	80
Rheumatology in the digital health era: status quo and quo vadis?	78
S100A4 inhibition targets fibrosis in SSc	77
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	76
Pain in systemic lupus erythematosus: emerging insights and paradigms	75
sCD13 role in arthritis mediated via bradykinin receptor	74
Targeting the IVD clock to halt degeneration	71
Antibiotics keep rheumatic heart disease at bay	71
Erosive cargo from synovial fibroblasts	70
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	68
Which DMARD for ICI-associated arthritis?	68
ERAP1 and the return of the UPR in ankylosing spondylitis	66
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	66
PGE2 receptor antagonist has potential to treat osteoarthritis	65
CAR T cells induce drug-free SLE remission	64
Macrophage-coated nanocarriers for gouty arthritis	63
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	59
A path towards personalized medicine for autoinflammatory and related diseases	59